Search Results - Rupert Austin
- Showing 1 - 3 results of 3
-
1
Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: An observational, prospective, controlled study by Bikalpa Neupane, Hitesh Pandya, Tej Pandya, Rupert Austin, Neil Spooner, James Rudge, Hussain Mulla
Published in Pharmacology Research & Perspectives (2022-10-01)Get full text
Article -
2
Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab by Peter N. Morcos, Jonathan Moss, Rupert Austin, Florian Hiemeyer, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Dirk Garmann
Published in CPT: Pharmacometrics & Systems Pharmacology (2023-11-01)Get full text
Article -
3
Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data by Stefan Willmann, Adam Lloyd, Rupert Austin, Shiju Joseph, Alexander Solms, Yang Zhang, Annika R. P. Schneider, Sebastian Frechen, Marcus‐Hillert Schultze‐Mosgau
Published in CPT: Pharmacometrics & Systems Pharmacology (2024-12-01)Get full text
Article